Stock MDGL MADRIGAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Madrigal Pharmaceuticals, Inc.

Equities

MDGL

US5588681057

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:41:21 2024-04-25 am EDT 		5-day change 1st Jan Change
192 USD -6.18% Intraday chart for Madrigal Pharmaceuticals, Inc. -12.40% -15.86%
Apr. 22 BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
Apr. 22 BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Madrigal Pharmaceuticals, Inc.

BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Says Rezdiffra Available in US MT
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing MT
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing MT
Evercore ISI Raises Price Target on Madrigal Pharmaceuticals to $405 From $325, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Madrigal Pharmaceuticals Prices $600 Million Public Offering MT
Madrigal Pharmaceuticals Starts $500 Million Public Offering MT
Madrigal plans $500 million fund raising to prepare for NASH drug launch RE
Madrigal commences $500 million public offering of common stock RE
North American Morning Briefing : Investors -2- DJ
TD Cowen Adjusts Madrigal Pharmaceuticals' Price Target to $390 From $349, Maintains Outperform Rating MT
Madrigal Pharmaceuticals Gets Added Boost with Rezdiffra Nod From FDA, B. Riley Says MT
Citigroup Adjusts Madrigal Pharmaceuticals' Price Target to $389 From $382, Maintains Buy Rating MT
Global markets live: Adobe, Ulta Beauty, Intel, Walt Disney, McDonald's... Our Logo
JMP Securities Adjusts Price Target on Madrigal Pharmaceuticals to $397 From $351, Maintains Market Outperform Rating MT
Old demons return as tech takes a dive Our Logo
Oppenheimer Adjusts Madrigal Pharmaceuticals Price Target to $375 From $320, Maintains Outperform Rating MT
H.C. Wainwright Adjusts Price Target on Madrigal Pharmaceuticals to $425 From $405, Maintains Buy Rating MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday MT

Chart Madrigal Pharmaceuticals, Inc.

Chart Madrigal Pharmaceuticals, Inc.
More charts

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
Biotechnology & Medical Research
Calendar
2024-05-07 - Q1 2024 Earnings Release
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
204.6 USD
Average target price
377.1 USD
Spread / Average Target
+84.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MADRIGAL PHARMACEUTICALS, INC. Stock Madrigal Pharmaceuticals, Inc.
-15.86% 4.3B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.90% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.67% 97.42B
ARGENX SE Stock argenx SE
+1.34% 22.2B
BIONTECH SE Stock BioNTech SE
-18.01% 21.23B
GENMAB A/S Stock Genmab A/S
-10.51% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.14% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.04% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+27.98% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. News Madrigal Pharmaceuticals, Inc.
  5. Earnings Flash (MDGL) MADRIGAL PHARMACEUTICALS Reports Q2 Loss $-4.14